Biogen

Biogen has revealed an agreement to acquire Reata Pharmaceuticals for approximately $7.3 billion. The news follows an announcement by the company last week that it would cut around 1,000 jobs, or 11% of its workforce, to allow investment into its product pipeline. In its second quarter results, the company said its new ‘Fit for Growth’ […]

A study that could lead to the development of new treatments for Parkinson’s disease has launched at the University of Dundee, Scotland. The study is utilising LRRK2 inhibitors developed by Denali Therapeutics and Biogen. Mutations in the LRRK2 protein kinase are the most frequent cause of inherited Parkinson’s disease and it is hoped that an […]

Leqembi’s prospects in the Alzheimer’s disease market remain uncertain despite its advantages over Aduhelm, says analytics company GlobalData.  Eisai and Biogen’s anti-amyloid beta (Aβ) monoclonal antibody (mAb), Leqembi (lecanemab), recently gained approval from the Food and Drug Administration (FDA) under the accelerated approval pathway for the treatment of Alzheimer’s disease (AD) in patients with early […]

Two start-ups have won a competition organised by EIT Health and pharmaceutical company Biogen which aimed at identifying solutions for Alzheimer’s disease.   French start-up Five Lives and Dutch start-up Neurocase were respectively placed first and second in the ‘neurotechprize’ competition. The winners were announced during a ceremony at the MedtecLIVE conference and will now receive […]